References
- Kushida CA, Nichols DA, Simon RD, et al. Symptom-based prevalence of sleep disorders in an adult primary care population. Sleep Breath 2000;4:11–5
- Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey I. Sleep 1999;22\(Suppl 2):S347–S353
- Lugaresi E, Zucconi M, Bixler EO. Epidemiology of sleep disorders. Psychiatr Annals 1987;17:446–53
- Dement WC. Rational basis for the use of sleeping pills. Int Pharmacopsychiatry 1982;17(Suppl 2):3–38
- Bliwise DL. Normal aging. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia (PA): W.B. Saunders Company; 2000:26–42
- Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, Blazer DG. Sleep complaints among elderly persons: an epidemiological study of three communities. Sleep 1995; 18:425–32
- Benca RM, Obermeyer WH, Thisted RA, Gillin C. Sleep and psychiatric disorders. Arch Gen Psychiatry 1992;49:651–68
- Vgontzas AN, Zoumakis M, Bixler EO, et al. Impaired nighttime sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 and cortisol levels: physiologic and therapeutic implications. J Clin Endocrinol Metab 2003; 88:2087–95
- Saletu B, Anderer P, Brandstatter N, et al. Insomnia in generalized anxiety disorder: polysomnographic, psychometric and clinical investigations before, during and after therapy with a long- versus a short-half-life benzodiazepine (quazepam versus triazolam). Neuropsychobiology 1994;29:69–90
- Lee JH, Reynolds CF, Hoch CC, et al. Electroencephalographic sleep in recently remitted, elderly depressed patients in double-blind placebo-maintenance therapy. Neuropsychopharmacology 1993;8:143–50
- Benca RM. Consequences of insomnia and its therapies. J Clin Psychiatry 2001;62(Suppl 10):33–8
- Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997;154:1417–23
- Roth T, Hajak G, Ustun TB. Consensus for the pharmacological management of insomnia in the new millennium. Int J Clin Pract 2001;55:42–52
- Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. Can Med Assoc J 2000;162:225–33
- Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. J Am Med Assoc 1997;278:2170–7
- Fry J, Scharf M, Mangano R, Fujimori M. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. Int Clin Psychopharmacol 2000;15:141–52
- Roth T, Roehrs TA. A review of the safety profiles of benzodiazepine hypnotics. J Clin Psychiatry 1991;52(Suppl):38–41
- Voshaar RC, van Balkom AJ, Zitman FG. Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study. Eur Neuropsychopharmacol 2004;14:301–6
- Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (part II). Clin Pharmacokinet 1991:21;262–73
- National Heart, Lung, and Blood Institute Working Group on Insomnia. Insomnia: assessment and management in primary care. Am Fam Physician 1999;59:3029–38. Available from http://www.aafp.org/afp/990600ap/3029.html [accessed 27 October 2003]
- Anon. Physicians’ desk reference®, 53rd ed. Montvale, NJ: Medical Economics Company, Inc; 1999:2075–8
- Locniskar A, Greenblatt DJ. Oxidative versus conjugative biotrans-formation of temazepam. Biopharm Drug Dispos 1990;11:499–506
- Roehrs T, Vogel G, Sterling W, Roth T. Dose effects of temazepam in transient insomnia. Arzneimittelforschung 1990;40:859–62
- Erman MK, Loewy D, Scharf MB. Comparison of temazepam 7.5 mg with temazepam 15 mg for the treatment of transient insomnia. Curr Med Res Opin 2004;20: 441–9
- Feinberg I, Maloney T, Campbell IG. Effects of hypnotics on the sleep EEG of healthy young adults: new data and psycho-pharmacologic implications. J Psychiatr Res 2000;34:423–38
- Monti JM, Alterwain P, Debellis J, Altier H, Pellejero T, Monti D. Short-term sleep laboratory evaluation of midazolam in chronic insomniacs. Arzneimittelforschung 1987;37:54–7
- Mitler MM, Carskadon MA, Phillips RL, et al. Hypnotic efficacy of temazepam: a long-term sleep laboratory evaluation. Br J Clin Pharmacol 1979;8:63S–68S
- Roehrs T, Vogel G, Vogel F, et al. Dose effects of temazepam tablets on sleep. Drugs Exp Clin Res 1986;12:693–9
- Agnew Jr HW, Webb WB, Williams RL. The first night effect: an EEG study of sleep. Psychophysiology 1966;2:263–6
- Rechtshaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Los Angeles (CA): Brian Information Services/Brain Research Institute, UCLA; 1968
- Vgontzas AN, Kales A, Bixler EO, Meyers DC. Temazepam 7.5 mg: effects on sleep in elderly insomniacs. Eur J Clin Pharmacol 1994;46: 209–13
- Data on file, Mallinckrodt Pharmaceuticals
- Bixler EO, Kales A, Soldatos CR, Scharf MB, Kales JD. Effectiveness of temazepam with short-, intermediate-, and long-term use: sleep laboratory evaluation. J Clin Pharmacol 1978;18:110–8
- Ferrillo F, Balestra V, Carta F, Nuvoli G, Pintus C, Rosadini G. Comparison between the central effects of camazepam and temazepam. Computerized analysis of sleep recordings. Neuro-psychobiology 1984;11:72–6
- Allaert F-A, Urbinelli R. Sociodemographic profile of insomniac patients across national surveys. CNS Drugs 2004;18\(Suppl 1):3–7
- Redline S, Kirchner HL, Quan SF, Gottlieb DJ, Kapur V, Newman A. The effects of age, sex, ethnicity, and sleep-disordered breathing on sleep architecture. Arch Intern Med 2004;164:406–18
- Gottlieb GL. Sleep disorders and their management. Special considerations in the elderly. Am J Med 1990;88(Suppl 3A): 29S–33S